%0 Journal Article
%T Cost of peripheral neuropathy in patients receiving treatment for
multiple myeloma: a US administrative claims analysis
%A Jerry Kagan
%A Kathleen L. Wilson
%A Sumeet Panjabi
%A Xue Song
%J Archive of "Therapeutic Advances in Hematology".
%D 2019
%R 10.1177/2040620719839025
%X Peripheral neuropathy (PN) is a common consequence of multiple myeloma (MM) among those commonly treated with older-generation proteasome inhibitors (PIs). In this study, we evaluated the economic burden attributable to PN among MM patients in real-world practice settings in the US
%K chemotherapy-induced neuropathy
%K healthcare costs
%K line of therapy
%K multiple myeloma
%K peripheral neuropathy
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444783/